Table 5.
Biological Samples | Nano-/Micro Materials | Detection Methods | Target | Limit of Detection (LOD) Linear Range (LR) |
Ref. |
---|---|---|---|---|---|
INFLUENZA VIRUSES | |||||
Virus samples in aqueous buffer and human serum | Ag@SiO2 nanoparticles | Metal enhanced fluorescence (MEF) | Influenza H5N1 | LOD: 3.5 ng/mL LR: 2–200 ng/mL |
[172] |
Clinical virus in complex biological samples | Au/Fe3O4 decorated graphene | Fluorescence | Influenza H1N1 | LOD: 7.27 fg/mL LR: 10–104 fg/mL |
[209] |
Complex biological samples | Au/iron oxides (Au/IONPs)-decorated graphene | Magnetofluoro immunoassay (Plasmonic-magnetic graphene platform for virus detection) | Influenza H1N1 In serum |
LOD: 6.07 pg/mL LR: – |
[209] |
Clinically isolated human serum samples | Silica-shelled magnetic nanobeads (MagNBs) and gold nanoparticles | Magnetic nano(e)zyme-linked immunosorbent assay (MagLISA) | Influenza virus A | LOD: 5 × 10−12 g/mL (by human eyes) LOD: 44.2 × 10−15 g/mL (by a microplate reader) LR: 5 × 10−15–5 × 10−6 g/mL |
[210] |
CORONAVIRUSES | |||||
SARS/MERS-CoV | |||||
Paired human sera and control serum samples for each hCoV |
Multiplexed magnetic microsphere | MMIA- multiplexed magnetic microsphere immunoassay Fluorescence |
SARS-CoV and MERS-CoV Immunoglobulin G antibodies specific for recombinant nucleocapsid proteins (from SARS-CoV, and MERS-CoV, hCoVs, 229E, NL63, OC43, HKU1 | LOD: – LR: – |
[211] |
2019-nCoV or SARS-CoV-2 | |||||
SARS-CoV-2 pseudovirus in 200 μL serum samples | Poly (amino ester) with carboxyl groups (PC)-coated magnetic nanoparticle (pcMNPs) | Fluorescence and convectional RT-PCR protocol |
Viral RNA extraction of SARS-CoV-2 | LOD: 10 copies of pseudovirus | [212] |
Fetal bovine serum (FBS) | Magnetic nanoparticle (MNP) | Optomagnetic sensing | SARS-CoV-2 RdRp coding sequences |
LOD: 0.4 fM dynamic Detection range: 3 orders of magnitude and a total assay time of ca. 100 min | [14] |